The Difference Between Temsirolimus and Everolimus

Temsirolimus (Temsirolimus) and everolimus (Everolimus) are two commonly used cancer treatment drugs. They both belong to a class of drugs called tyrosine kinase inhibitors (mTOR inhibitors). Although they have some similarities, there are also some differences. Everolimus is a drug approved for the treatment of patients with metastatic renal cell carcinoma after disease progression on vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). Temsirolimus is mainly used to treat advanced renal cell carcinoma.

Everolimus and temsirolimus have been studied extensively in clinical trials. The two mTOR inhibitors temsirolimus and everolimus have been shown to be effective in advanced renal cell carcinoma but have never been compared in prospective trials. Everolimus can be administered orally or orally, usually once daily. Temsirolimus, on the other hand, is given by intravenous injection, usually once a week. Both drugs can cause a range of side effects, such as fatigue, nausea, vomiting, mouth sores, and more. However, the specific appearance and severity of side effects may vary.

The original drug temsirolimus has not yet been marketed in China, and therefore cannot be included in domestic medical insurance. The original temsirolimus drug marketed overseas has a Turkish version and a European version. The ingredients of the two are basically the same. The price of each box of 30mg/1.2mL may be more than 10,000 yuan, and the price of 25mg/mL may be around 3,000 yuan per box (the price may fluctuate due to exchange rates). There is currently no generic version of temsirolimus available on the market. For more drug information and specific prices, please consult a medical consultant.